公司资料
Arcus Biosciences 股价、新闻与催化剂
- 股票代码:
- RCUS
- 交易所:
- NYSE
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
29.56 USD (+0.27%)
收盘价
最后更新: 2026年8月17日
3.08B USD
市值
股价为何变动
As of Aug 17, 2026, RCUS closed up 0.27% at $29.56. No new same-company headline was identified in the current news window.
公司概览
业务概览
Arcus Biosciences is an oncology company focused on immuno-oncology combinations and targeted cancer therapies. Its platform is built to create differentiated regimens in solid tumors.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Arcus sits in clinical-stage oncology biotechnology.
商业模式特征
The company depends on clinical data, partnership economics, and the ability to translate combination science into durable cancer programs.
生物医药行业定位
Arcus is a catalyst-sensitive oncology name whose stock moves on readouts, combination strategy, and partner progress.
未来催化剂
- Arcus's catalysts are domvanalimab/zimberelimab combinations and casdatifan in oncology, where the next readouts determine whether the platform can keep its premium. The company remains a key immuno-oncology and HIF-2α story.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。